Sontuzumab

N/A

Report date: 2023/04/21 13:58:40

Base Information

Drug NameSontuzumab
Drug Alias NameMonoclonal antibody HMFG1TherexBTH-1704AS-1402R-1550 +[6
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunostimulantsMucin-1 inhibitors
TargetsMucin-1
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesRussian Federation
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCancer Research UK
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A